BioLineRx Ltd.
BioLineRx Ltd. (NASDAQ: BLRX) is trading at $2.60, about ₹249 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, up 3.17% today. Indian residents can buy BioLineRx from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$2.49
Today's high
$2.60
52 week low
$2.15
52 week high
$4.56
BLRX opened at $2.49, closed previously at $2.52, and has traded between $2.15 and $4.56 over the past 52 weeks.
About
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Key statistics
Avg. volume
39.95K
Market cap
$11.31M
P/E Ratio
-1.38
Price-to-sales ratio
7.95
Enterprise value
$14.48M
Free cash flow yield
-98.51%
Debt-to-equity ratio
0.58
Return on equity
-47.22%
ROIC
-50.11%
Beta
0.69
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$1.19M
Earnings per share
-$0.29
Free cash flow
-$8.16M
Net profit margin
-574.17%
Gross margin
69.79%
EBITDA
-$224.77K
Revenue growth
-95.89%
Similar securities
This is not an investment recommendation
How to buy BioLineRx from India
Indian residents can buy BioLineRx shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for BioLineRx and place an order
Find BioLineRx by name or by its ticker, BLRX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. BioLineRx trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your BioLineRx position in USD and INR. BioLineRx pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in BioLineRx from India
Trading and taxes when buying BioLineRx from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneBioLineRx does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy BioLineRx stock?
Yes. BioLineRx (BLRX) has been listed on NASDAQ since 2011, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one BioLineRx share cost in rupees?
One BioLineRx share is $2.60 — about ₹249 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the BioLineRx price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying BioLineRx from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of BioLineRx?
Yes. One BioLineRx share is $2.60, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in BioLineRx.
How are gains on BioLineRx shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the BioLineRx price. Paasa issues a capital-gains statement for your return.
Does BioLineRx pay a dividend?
No. BioLineRx does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade BioLineRx from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is BioLineRx a United States company, and does that change how it is taxed?
BioLineRx trades on NASDAQ in US dollars, but the company is domiciled in Israel. BioLineRx trades as an American Depositary Receipt rather than an ordinary share. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.
Do I have to declare BioLineRx shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your BioLineRx holding, its cost and its closing value.
How do I sell BioLineRx and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.